NCT01606254View on ClinicalTrials.gov

A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Schizophrenia
Interventions
DRUG

Paliperidone palmitate

Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.

Trial Locations (1)

Unknown

Ichikawa

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY